Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
Market access is increasingly shaping biopharma decisions earlier in the lifecycle. This article explores how policy uncertainty, evidence expectations, and access strategy are influencing development, investment, and long-term value realization.
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.
Congress is considering changes that would significantly alter how Pharmacy Benefit Managers (PBMs) are compensated in commercial insurance. See our report and full analysis.
How a biotech company equipped HCPs to navigate acquisition, coding, and coverage for a dual-therapy regimen.
How program management and strategic alignment prepared a biopharma company for NDA submission and launch.
How a manufacturer integrated imaging requirements into its access and patient support strategy.
How payer research helped refine value messaging, pricing strategy, and evidence plans.
How a pharmaceutical company built a compliant, scalable 340B contract pharmacy program.
Real-world evidence is no longer just a regulatory checkbox—it’s a strategic driver of pricing, access, and payer engagement. Discover how leading life sciences teams are embedding RWE earlier to shape reimbursement strategy, optimize launch planning, and unlock value-based contracts.